IS7744A - Eikósapentanó sýra (EPA) til notkunar við meðhöndlun á lystarstoli (AN) og matgræðgi - Google Patents

Eikósapentanó sýra (EPA) til notkunar við meðhöndlun á lystarstoli (AN) og matgræðgi

Info

Publication number
IS7744A
IS7744A IS7744A IS7744A IS7744A IS 7744 A IS7744 A IS 7744A IS 7744 A IS7744 A IS 7744A IS 7744 A IS7744 A IS 7744A IS 7744 A IS7744 A IS 7744A
Authority
IS
Iceland
Prior art keywords
anorexia
epa
graft
treatment
eicosapentanoic acid
Prior art date
Application number
IS7744A
Other languages
English (en)
Icelandic (is)
Inventor
Frederick Horrobin David (l βtinn)
Ayton Agnes
Original Assignee
Amarin Neuroscience Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7744(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amarin Neuroscience Limited filed Critical Amarin Neuroscience Limited
Publication of IS7744A publication Critical patent/IS7744A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
IS7744A 2002-09-16 2005-03-15 Eikósapentanó sýra (EPA) til notkunar við meðhöndlun á lystarstoli (AN) og matgræðgi IS7744A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0221480.7A GB0221480D0 (en) 2002-09-16 2002-09-16 Treatment of anorexia nervosa (AN) and bulimia
PCT/GB2003/003985 WO2004024136A1 (en) 2002-09-16 2003-09-16 Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia

Publications (1)

Publication Number Publication Date
IS7744A true IS7744A (is) 2005-03-15

Family

ID=9944164

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7744A IS7744A (is) 2002-09-16 2005-03-15 Eikósapentanó sýra (EPA) til notkunar við meðhöndlun á lystarstoli (AN) og matgræðgi

Country Status (20)

Country Link
US (1) US20060135608A1 (enExample)
EP (1) EP1556028A1 (enExample)
JP (1) JP2006503031A (enExample)
KR (1) KR20050042823A (enExample)
CN (1) CN1694694A (enExample)
AU (1) AU2003269138A1 (enExample)
BR (1) BR0317857A (enExample)
CA (1) CA2499142A1 (enExample)
GB (1) GB0221480D0 (enExample)
HR (1) HRP20050245A2 (enExample)
IS (1) IS7744A (enExample)
MX (1) MXPA05002943A (enExample)
NO (1) NO20051847L (enExample)
NZ (1) NZ538793A (enExample)
PL (1) PL375726A1 (enExample)
RS (1) RS20050226A (enExample)
RU (1) RU2330653C2 (enExample)
TW (1) TW200410682A (enExample)
WO (1) WO2004024136A1 (enExample)
ZA (1) ZA200502161B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
WO2005046668A1 (ja) * 2003-11-14 2005-05-26 Mochida Pharmaceutical Co., Ltd. 言語障害予防・治療剤
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および/又はうつ症状の改善作用を有する組成物
US8383677B2 (en) 2006-12-28 2013-02-26 Suntory Holdings Limited Nerve-regenerating agent
DK2121576T3 (en) 2007-02-15 2016-02-15 Ct De Rech Sur Les Biotechnologies Marine Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US8816110B2 (en) 2007-02-15 2014-08-26 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
AU2008229604B2 (en) 2007-03-20 2013-05-30 Scf Pharma Inc. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
SMT201800261T1 (it) * 2009-06-15 2018-07-17 Amarin Pharmaceuticals Ie Ltd Composizioni e metodi per abbassare i trigliceridi senza aumentare i livelli di ldl-c in un soggetto in concomitanza con la terapia con statine
CA2825037A1 (en) * 2011-02-11 2012-08-16 E.I. Du Pont De Nemours And Company An eicosapentaenoic acid concentrate
US9447020B2 (en) 2013-10-31 2016-09-20 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
RU2545988C1 (ru) * 2013-11-12 2015-04-10 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы Способ лечения хронического запора и функциональной анорексии
WO2019153073A1 (en) 2018-02-07 2019-08-15 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
US20210130897A1 (en) * 2018-04-16 2021-05-06 Quadrant Biosciences Inc. Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status
WO2019210424A1 (en) 2018-05-03 2019-11-07 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
CN109276262B (zh) * 2018-07-30 2021-01-26 中国科学院心理研究所 一种用于筛选高危进食障碍的检测系统
US12226390B2 (en) 2019-07-21 2025-02-18 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
EP4125836A1 (en) * 2020-03-27 2023-02-08 Homeostasis Therapeutics, Limited Method of treatment for anorexia nervosa, bulimia and related clinical syndromes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes

Also Published As

Publication number Publication date
TW200410682A (en) 2004-07-01
US20060135608A1 (en) 2006-06-22
CA2499142A1 (en) 2004-03-25
GB0221480D0 (en) 2002-10-23
ZA200502161B (en) 2005-09-15
AU2003269138A1 (en) 2004-04-30
WO2004024136A1 (en) 2004-03-25
JP2006503031A (ja) 2006-01-26
PL375726A1 (en) 2005-12-12
NZ538793A (en) 2007-05-31
MXPA05002943A (es) 2005-06-03
RU2330653C2 (ru) 2008-08-10
CN1694694A (zh) 2005-11-09
HRP20050245A2 (en) 2005-10-31
KR20050042823A (ko) 2005-05-10
RS20050226A (sr) 2007-09-21
BR0317857A (pt) 2005-12-06
EP1556028A1 (en) 2005-07-27
RU2005107416A (ru) 2006-01-20
NO20051847L (no) 2005-04-15

Similar Documents

Publication Publication Date Title
IS7744A (is) Eikósapentanó sýra (EPA) til notkunar við meðhöndlun á lystarstoli (AN) og matgræðgi
NO20034430D0 (no) Tiohydantoiner og anvendelse derav for behandling av diatbetes
IS8267A (is) [1,8]naftýridín-2-ón og tengd efnasambönd til notkunar við meðferð á geðklofa
NO20052139L (no) Bandasje og epidermal posisjoneringsmekanisme og fremgangsmate for anvendelse av samme
NO20022286D0 (no) Fasesementeringsverktöy for tynne hull og fremgangsmåte
EE05015B1 (et) Makseterminaliseade mgipunktiseadme hendamiseks, maksessteem ja makseprotseduuri teostamise meetod
DK1404873T3 (da) Kimæriske immunmodulatoriske forbindelser og fremgangsmåder til anvendelse deraf
NO20012689D0 (no) Nye fluider og teknikker for matriks syrebehandling
NO20042147L (no) Heterocykliske forbindelser og fremgangsmater for anvendelse derav
DK1216342T3 (da) Undervandssmöreapparat og fremgangsmåder til at cirkulere fluider i et undervandssmöreapparat
TWI341551B (en) Stage apparatus and light exposing apparatus
DK1375647T3 (da) Kunstig dermis og fremstillingsfremgangsmåde dertil
NO20042700L (no) Kraftforsyningssystem og elektronisk innretning som omfatter systemet
DK1697564T3 (da) Elektropoleringsanordning og fremgangsmåde for medicinske implantater
IS7348A (is) N-pýrasínýl-fenýlsúlfónamíð og notkun þeirra til að meðhöndla flakkboðatengda sjúkdóma
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
IS7444A (is) Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum
ITTO20001156A0 (it) Apparecchiatura per il trattamento di disgregazione di campioni biologici e dispositivo disgregatore per l'impiego in detta apparecchiatura.
DK1027086T3 (da) Formede legemer til anvendelse som implantater i humanmedicin og metode til fremstilling af sådanne formede legemer
NO20034827L (no) Bearbeidingshjelpemiddel og fremgangsmåte for bearbeiding av polymerer
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
ITMI20021552A1 (it) Dispositivo per il trattamento di sangue in circuito extracorporeo
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
NO996017L (no) Kombinert krafttang med integrert slamavsug og gjengedopingsapparat
IS7962A (is) Þíenópýridasínón og notkun þeirra í breytingu á sjálfsnæmissjúkdómi